OBJECTIVES: To determine predictors of permanent pacemaker (PPM) implantation up to 30 days after transcatheter aortic valve implantation (TAVI) in a prospective multicenter registry. BACKGROUND: Conduction disorders requiring PPM implantation are one of the most common complications seen after TAVI. Knowledge about possible predictors may help to decrease the rate of PPM implantations. METHODS: In total, 1347 consecutive patients who underwent TAVI in 22 centers were prospectively enrolled in the German transcatheter aortic valve interventions registry. Both Medtronic CoreValve™ and Edwards Sapien™ valves were implanted. Patients with preprocedurally implanted PPM or implantable cardioverter defibrillator were excluded from the analysis (n = 199). Regression analysis of baseline and procedure characteristics of the remaining 1,147 patients was performed. RESULTS: Procedural success was achieved in 97.4% of the cases. The rate for PPM after TAVI was 33.7%. The absence of prior valve surgery, the use of Medtronic CoreValve™ prosthesis and the presence of a porcelain aorta were identified as independent predictors for PPM after TAVI. Mortality at 30 days did not differ between patients with or without PPM necessity (6.0% vs. 8.1%, respectively; HR 0.72; CI (0.45-1.16); P = 0.17). CONCLUSIONS: PPM is a common postprocedure requirement after TAVI. The absence of prior valve surgery, the implantation of Medtronic CoreValve™ prosthesis, and the presence of a porcelain aorta were independently associated with PPM after TAVI.
OBJECTIVES: To determine predictors of permanent pacemaker (PPM) implantation up to 30 days after transcatheter aortic valve implantation (TAVI) in a prospective multicenter registry. BACKGROUND:Conduction disorders requiring PPM implantation are one of the most common complications seen after TAVI. Knowledge about possible predictors may help to decrease the rate of PPM implantations. METHODS: In total, 1347 consecutive patients who underwent TAVI in 22 centers were prospectively enrolled in the German transcatheter aortic valve interventions registry. Both Medtronic CoreValve™ and Edwards Sapien™ valves were implanted. Patients with preprocedurally implanted PPM or implantable cardioverter defibrillator were excluded from the analysis (n = 199). Regression analysis of baseline and procedure characteristics of the remaining 1,147 patients was performed. RESULTS: Procedural success was achieved in 97.4% of the cases. The rate for PPM after TAVI was 33.7%. The absence of prior valve surgery, the use of Medtronic CoreValve™ prosthesis and the presence of a porcelain aorta were identified as independent predictors for PPM after TAVI. Mortality at 30 days did not differ between patients with or without PPM necessity (6.0% vs. 8.1%, respectively; HR 0.72; CI (0.45-1.16); P = 0.17). CONCLUSIONS: PPM is a common postprocedure requirement after TAVI. The absence of prior valve surgery, the implantation of Medtronic CoreValve™ prosthesis, and the presence of a porcelain aorta were independently associated with PPM after TAVI.
Authors: Anna Kostopoulou; Panagiotis Karyofillis; Efthimios Livanis; George Karavolias; George Theodorakis; John Paraskevaides; Vassilis Voudris Journal: Curr Treat Options Cardiovasc Med Date: 2016-02
Authors: Christiana Schernthaner; Johannes Kraus; Franz Danmayr; Matthias Hammerer; Jens Schneider; Uta C Hoppe; Bernhard Strohmer Journal: Wien Klin Wochenschr Date: 2016-01-08 Impact factor: 1.704
Authors: Cláudio Monteiro; Andres Di Leoni Ferrari; Paulo Ricardo Avancini Caramori; Luiz Antonio Ferreira Carvalho; Dimytri Alexandre de Alvim Siqueira; Luiz Eduardo Koenig São Thiago; Marco Perin; Valter C de Lima; Enio Guérios; Fabio Sandoli De Brito Junior Journal: Arq Bras Cardiol Date: 2017-11-27 Impact factor: 2.000
Authors: Jochen Reinöhl; Klaus Kaier; Anja Gutmann; Stefan Sorg; Constantin von Zur Mühlen; Matthias Siepe; Hardy Baumbach; Martin Moser; Annette Geibel; Andreas Zirlik; Philipp Blanke; Werner Vach; Friedhelm Beyersdorf; Christoph Bode; Manfred Zehender Journal: BMC Cardiovasc Disord Date: 2015-10-22 Impact factor: 2.298
Authors: Antonio Mangieri; Claudio Montalto; Matteo Pagnesi; Giuseppe Lanzillo; Ozan Demir; Luca Testa; Antonio Colombo; Azeem Latib Journal: Front Cardiovasc Med Date: 2018-07-03
Authors: Talal Aljabbary; Feng Qiu; Shannon Masih; Jiming Fang; Gabby Elbaz-Greener; Peter C Austin; Josep Rodés-Cabau; Dennis T Ko; Sheldon Singh; Harindra C Wijeysundera Journal: JAMA Netw Open Date: 2018-05-18